Mirror Skin prioritizes bioavailable active ingredients so each drop delivers meaningful support for your skin's appearance and overall health
Therefore, CB-839 has been tested in many clinical trials, including colorectal cancer (NCT02861300), triple-negative breast cancer (NCT02071862), renal cell carcinoma (NCT03163667), melanoma (NCT02771626), and others (Table 2)
Ribaldone D, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, Giordanino C, Baronio M, De Angelis C, Saracco G, Pellicano R (2019) Rifabutin-based rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients
Every subsequent draw from the same vial occurs from an increasingly contaminated solution